カテゴリ： GlobalData, オランダ, 企業調査

Qiagen NV (QIA)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Qiagen NV (QIA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013401
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：117
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：オランダ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Qiagen NV (Qiagen) is a provider of molecular testing solutions. Its solutions include sample and assay technologies, bioinformatics and automation systems. Qiagen’s sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue. The company’s product portfolio includes consumable products, automated solutions for sample collection, and open and target specific assays. Qiagen also supplies diagnostic test kits and assays for human and veterinary molecular diagnostics. The company serves animal pathogens and genotyping, cancer research, and environmental water testing, among other sectors. Qiagen offers solutions to pharmaceutical and biotechnology companies, and research institutions. It has operations across the Americas; Europe, the Middle East, Africa, and Asia Pacific. Qiagen is headquartered in Venlo, the Netherlands.

Qiagen NV (QIA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Qiagen NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Qiagen NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Qiagen NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Qiagen NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Qiagen NV, Medical Devices Deals, 2011 to YTD 2017 12
Qiagen NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Qiagen NV, Pharmaceuticals & Healthcare, Deal Details 17
Venture Financing 17
Numaferm Raises Additional Funds through Seed Financing 17
Exosome Diagnostics Raises USD60 Million in Series B Financing Round 18
Protagen Raises USD12.5 Million in Venture Financing 20
Curetis Raises USD18 Million in Extended Series B Venture Financing 21
Private Equity 23
Sobera Capital And Triginta Capital Divest Stake In Biobase Through Management Buyout 23
Partnerships 24
Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 24
Biobase Enters Into Licensing Agreement With University of Southern California And Children’s Hospital of Philadelphia 25
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 26
Bristol-Myers Squibb and Qiagen Enter into Agreement 27
Qiagen Enters into Agreement with Genohm 28
Qiagen Enters into Agreement with Mirati Therapeutics 29
DNAnexus Enters into Partnership with Qiagen 30
Qiagen Enters into Agreement with GATC Biotech 31
Tokai Pharma Expands Agreement with Qiagen 32
Tokai Pharma Expands Agreement with Qiagen 33
Qiagen Enters into Agreement with ArcherDx 34
Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 35
AstraZeneca Enters into Co-Development Agreement with Qiagen 36
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 37
Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 38
Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 40
Takara Bio Enters Into Co-Marketing Agreement With Exiqon For miRCURY LNA Products 41
ShanghaiBio Enters Into Agreement With Ingenuity Systems 42
Atlas Biolabs Enters Into Agreement With Ingenuity Systems 43
Convey Computer Enters Into Technology Integration Agreement With CLC bio 44
QIAGEN Enters Into Joint Venture Agreement With Bio-X Center 45
Labcyte Enters Into Technology Integration Agreement With QIAGEN 46
CLC bio Enters Into Technology Integration Agreement With BIOBASE 47
Exiqon Enters Into Distribution Agreement With Tataa Biocenter 48
Exiqon Enters Into Distribution Agreement With Bioneer 49
Exiqon Enters Into Co-Marketing Agreement With Biotika 50
Ingenuity Systems Expands Collaboration With Integromics 51
IPSOGEN Enters Into Distribution Agreement With Sysmex 52
Ingenuity Systems Enters Into Research Collaboration With Covance Genomics 53
Ingenuity Systems Enters Into Co-Development Agreement With Erasmus University 54
Licensing Agreements 55
Exiqon Enters into Licensing Agreement with Aarhus University Hospital 55
Inserm Transfert Enters into Licensing Agreement with HalioDx 56
Transgenomic Expands Licensing Agreement with Exiqon 57
Roche Molecular Enters into Licensing Agreement with Qiagen 58
Exiqon Enters into Licensing Agreement with Aarhus University Hospital 59
Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 60
Sygnis Pharma Enters Into Licensing Agreement With Qiagen For Amplification Buffer 61
Helicos BioSciences Enters Into Licensing Agreement With Intelligent Bio-Systems For Single Molecule Sequencing Technology Patents 62
Genetrix Enters Into Licensing Agreement With Qiagen For Qualiphi 63
Idexx Labs Enters Into Licensing Agreement With Exiqon For Locked Nucleic Acids Technology 64
Equity Offering 65
Exiqon Completes Private Placement Of Shares For US$2.6 Million 65
Debt Offering 66
Qiagen Raises USD400 Million in Private Placement of Notes 66
Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 67
Qiagen Completes Public Offering Of Senior Notes Due 2019 For US$430 Million 68
Qiagen Completes Public Offering Of Senior Notes Due 2021 For US$300 Million 69
Exiqon Completes Private Placement Of Bonds For US$3 Million 70
Acquisition 71
Qiagen Acquires OmicSoft 71
Qiagen Acquires Exiqon for up to USD102.4 Million 72
Qiagen Acquires MO BIO Labs 74
Qiagen Acquires Enzymatics 75
Qiagen Acquires Biobase 76
Qiagen Acquires Ingenuity Systems For US$105 Million 77
CLC bio Acquires Molegro, Developer Of Drug Discovery Software 79
Qiagen Acquires Intelligent Bio-Systems 80
Qiagen Completes Acquisition Of Additional 26.7% Stake In Ipsogen For US$30 Million 81
Qiagen Completes Acquisition Of Cellestis 83
QIAGEN Acquires Minority Stake In Alacris Theranostics For US$3.4 Million 85
Qiagen NV – Key Competitors 86
Qiagen NV – Key Employees 87
Qiagen NV – Locations And Subsidiaries 88
Head Office 88
Other Locations & Subsidiaries 88
Joint Venture 91
Recent Developments 92
Financial Announcements 92
Jul 27, 2017: QIAGEN Reports Results for Second Quarter and First Half of 2017 92
May 02, 2017: QIAGEN reports results for first quarter 2017 95
Feb 01, 2017: QIAGEN Reports Results for Fourth Quarter and Full-year 2016 97
Nov 02, 2016: QIAGEN Reports Results for Third Quarter and First Nine Months of 2016 101
Jul 28, 2016: QIAGEN Reports Results for Second Quarter of 2016; Increased Commitment to Return $300 Million of Capital to Shareholders by End-2017 104
Apr 27, 2016: QIAGEN Reports Results for First Quarter of 2016 107
Feb 02, 2016: QIAGEN Reports Results for Fourth Quarter and Full-Year 2015 110
Product News 114
Oct 20, 2016: QIAGEN launches QIAscout for single-cell isolation 114
Feb 11, 2016: QIAGEN Launches Targeted RNA Panels for Next-generation Sequencing 115
Other Significant Developments 116
Nov 02, 2016: QIAGEN launches restructuring initiatives, revises outlook for 2016 earnings and provides initial net sales and adjusted earnings guidance for 2017 116
Appendix 117
Methodology 117
About GlobalData 117
Contact Us 117
Disclaimer 117

List of Tables
Qiagen NV, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Qiagen NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Qiagen NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Qiagen NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Qiagen NV, Deals By Therapy Area, 2011 to YTD 2017 11
Qiagen NV, Medical Devices Deals, 2011 to YTD 2017 12
Qiagen NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Numaferm Raises Additional Funds through Seed Financing 17
Exosome Diagnostics Raises USD60 Million in Series B Financing Round 18
Protagen Raises USD12.5 Million in Venture Financing 20
Curetis Raises USD18 Million in Extended Series B Venture Financing 21
Sobera Capital And Triginta Capital Divest Stake In Biobase Through Management Buyout 23
Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 24
Biobase Enters Into Licensing Agreement With University of Southern California And Children’s Hospital of Philadelphia 25
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 26
Bristol-Myers Squibb and Qiagen Enter into Agreement 27
Qiagen Enters into Agreement with Genohm 28
Qiagen Enters into Agreement with Mirati Therapeutics 29
DNAnexus Enters into Partnership with Qiagen 30
Qiagen Enters into Agreement with GATC Biotech 31
Tokai Pharma Expands Agreement with Qiagen 32
Tokai Pharma Expands Agreement with Qiagen 33
Qiagen Enters into Agreement with ArcherDx 34
Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 35
AstraZeneca Enters into Co-Development Agreement with Qiagen 36
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 37
Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 38
Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 40
Takara Bio Enters Into Co-Marketing Agreement With Exiqon For miRCURY LNA Products 41
ShanghaiBio Enters Into Agreement With Ingenuity Systems 42
Atlas Biolabs Enters Into Agreement With Ingenuity Systems 43
Convey Computer Enters Into Technology Integration Agreement With CLC bio 44
QIAGEN Enters Into Joint Venture Agreement With Bio-X Center 45
Labcyte Enters Into Technology Integration Agreement With QIAGEN 46
CLC bio Enters Into Technology Integration Agreement With BIOBASE 47
Exiqon Enters Into Distribution Agreement With Tataa Biocenter 48
Exiqon Enters Into Distribution Agreement With Bioneer 49
Exiqon Enters Into Co-Marketing Agreement With Biotika 50
Ingenuity Systems Expands Collaboration With Integromics 51
IPSOGEN Enters Into Distribution Agreement With Sysmex 52
Ingenuity Systems Enters Into Research Collaboration With Covance Genomics 53
Ingenuity Systems Enters Into Co-Development Agreement With Erasmus University 54
Exiqon Enters into Licensing Agreement with Aarhus University Hospital 55
Inserm Transfert Enters into Licensing Agreement with HalioDx 56
Transgenomic Expands Licensing Agreement with Exiqon 57
Roche Molecular Enters into Licensing Agreement with Qiagen 58
Exiqon Enters into Licensing Agreement with Aarhus University Hospital 59
Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 60
Sygnis Pharma Enters Into Licensing Agreement With Qiagen For Amplification Buffer 61
Helicos BioSciences Enters Into Licensing Agreement With Intelligent Bio-Systems For Single Molecule Sequencing Technology Patents 62
Genetrix Enters Into Licensing Agreement With Qiagen For Qualiphi 63
Idexx Labs Enters Into Licensing Agreement With Exiqon For Locked Nucleic Acids Technology 64
Exiqon Completes Private Placement Of Shares For US$2.6 Million 65
Qiagen Raises USD400 Million in Private Placement of Notes 66
Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 67
Qiagen Completes Public Offering Of Senior Notes Due 2019 For US$430 Million 68
Qiagen Completes Public Offering Of Senior Notes Due 2021 For US$300 Million 69
Exiqon Completes Private Placement Of Bonds For US$3 Million 70
Qiagen Acquires OmicSoft 71
Qiagen Acquires Exiqon for up to USD102.4 Million 72
Qiagen Acquires MO BIO Labs 74
Qiagen Acquires Enzymatics 75
Qiagen Acquires Biobase 76
Qiagen Acquires Ingenuity Systems For US$105 Million 77
CLC bio Acquires Molegro, Developer Of Drug Discovery Software 79
Qiagen Acquires Intelligent Bio-Systems 80
Qiagen Completes Acquisition Of Additional 26.7% Stake In Ipsogen For US$30 Million 81
Qiagen Completes Acquisition Of Cellestis 83
QIAGEN Acquires Minority Stake In Alacris Theranostics For US$3.4 Million 85
Qiagen NV, Key Competitors 86
Qiagen NV, Key Employees 87
Qiagen NV, Other Locations 88
Qiagen NV, Subsidiaries 88
Qiagen NV, Joint Venture 91

★海外企業調査レポート[Qiagen NV (QIA)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Gedeon Richter Plc：企業の戦略・SWOT・財務情報
    Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report Summary Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Lunaphore Technologies SA：医療機器：M&Aディール及び事業提携情報
    Summary Lunaphore Technologies SA (Lunaphore) is a medical device company that develops tissue processing solutions for inmmunohistochemistry. The company builds tumor analysis and classification platforms based on a microfluidic technologies. It offers FFeX, a fast fluidic exchange technology that …
  • Beneo GmbH：企業の戦略・SWOT・財務分析
    Beneo GmbH - Strategy, SWOT and Corporate Finance Report Summary Beneo GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • BBX Capital Corporation：戦略・SWOT・企業財務分析
    BBX Capital Corporation - Strategy, SWOT and Corporate Finance Report Summary BBX Capital Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • The 77 Bank Ltd：企業の戦略・SWOT・財務情報
    The 77 Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary The 77 Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Autoliv, Inc.：企業の戦略・SWOT・財務情報
    Autoliv, Inc. - Strategy, SWOT and Corporate Finance Report Summary Autoliv, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • NaturalNano Inc (NNAN)：企業の財務・戦略的SWOT分析
    Summary NaturalNano Inc (NaturalNano) is a nanomaterial company that develops and offers proprietary technologies and processes to provide nanotubes. The company’s products include PleximerTM, a turnkey HNT polymer concentrate available in pellet form that can be added directly into a polymer extrud …
  • Siemens Healthcare GmbH：医療機器：M&Aディール及び事業提携情報
    Summary Siemens Healthcare GmbH d/b/a Siemens Healthineers, a subsidiary of Siemens AG, is a global medical device company that designs, develops, manufactures and distributes medical devices and technologies for diagnostic markets. Its major products include healthcare IT, laboratory diagnostics eq …
  • Dawnrays Pharmaceutical (Holdings) Ltd (2348)：企業の財務・戦略的SWOT分析
    Summary Dawnrays Pharmaceutical (Holdings) Ltd (Dawnrays) is a manufacturer of cephalosporin antibiotics and specific medicines. The company provides products such as cefoperazone sodium and sulbactam sodium sterile, cefoperazone sodium sterile, ceftazidime sterile, cefixme, ceftriaxone sodium crude …
  • Shanghai Electric Group Co Ltd：企業の戦略・SWOT・財務情報
    Shanghai Electric Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Shanghai Electric Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Texas A&M University：製薬・医療：M&Aディール及び事業提携情報
    Summary Texas A&M University (TAMU) is a research based university that provide educational and research services. The university offers undergraduate, graduate and professional courses to its students. It consists of various colleges and departments such as College of Agriculture and Life Sciences, …
  • Dine Brands Global, Inc. (DIN)：企業の財務・戦略的SWOT分析
    Dine Brands Global, Inc. (DIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Dairy Crest Group plc：企業の戦略・SWOT・財務情報
    Dairy Crest Group plc - Strategy, SWOT and Corporate Finance Report Summary Dairy Crest Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • New Zealand Energy Corp (NZ)：企業の財務・戦略的SWOT分析
    Summary New Zealand Energy Corp (New Zealand Energy), formerly East Coast Energy Ventures Ltd is an oil and gas company. The company carries out the business of production, development and exploration of conventional and unconventional oil and natural gas prospects in New Zealand. It acquires strate …
  • Clientele Limited
    Clientele Limited - Strategy, SWOT and Corporate Finance Report Summary Clientele Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Allscripts Healthcare Solutions Inc (MDRX)：企業の財務・戦略的SWOT分析
    Allscripts Healthcare Solutions Inc (MDRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Kajima Corp (1812)：企業の財務・戦略的SWOT分析
    Kajima Corp (1812) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Eisai Co., Ltd.：企業の戦略・SWOT・財務分析
    Eisai Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Eisai Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • CardioGenics Inc：企業の製品パイプライン分析2018
    Summary CardioGenics Inc (CardioGenics), a subsidiary of CardioGenics Holdings Inc is a medical device company that manufactures sensitive diagnostic test products to the in-vitro diagnostics market. The company’s products include QL care analyzer, immunoassay tests, and paramagnetic beads, among ot …
  • Asseco Poland S.A.：企業のM&A・事業提携・投資動向
    Asseco Poland S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Asseco Poland S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆